Sentynl Therapeutics, Inc. v. U.S. Specialty Insurance Company
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA 10 SENTYNL THERAPEUTICS, INC., CASE NO. 19cv1667-LAB-AHG 11 Plaintiff, ORDER: 12 v. 1) GRANTING DEFENDANT’S MOTION FOR SUMMARY
U.S. SPECIALTY INSURANCE CO.,
JUDGMENT [Dkt. 64];
Defendants. 2) DENYING PLAINTIFF’S CROSS-
MOTION FOR SUMMARY
JUDGMENT [Dkt. 73];
17 3) DENYING MOTION TO EXCLUDE AS MOOT [Dkt. 84]; and 19 4) DENYING MOTION FOR JUDGMENT ON THE PLEADINGS AS MOOT [Dkt. 41]
22 The question in this case is whether an insurance policy exclusion for 23 claims “arising out of” a business’s products is broad enough, under 24 California law, to encompass not only claims for product liability, but also 25 claims for business practices tied to those products. Sentynl Therapeutics, 26 Inc. markets and sells two products, Levorphanol and Abstral, both 27 prescription opioid medications. After receiving a …